INFIBEMA
The computed 12-month bankruptcy probability of INFIBEMA is 0.1% (very low). The 2025 annual accounts show equity of €61k and a net result of €-4k. Equity is growing by ~3.6% per year across the filed fiscal years. Its solvency ranks better than 46% of 2208 sector peers (fiscal year 2025). The company has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €61k |
| Net result | €-4k |
| Better than sector | 46% |
| Active | 16 yrs |
Strong profile, led by stability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 50.9% | 58.2% | |
| Net result | €-4k | €60k | |
| Equity | €61k | €74k | |
| Gross operating margin | €27k | €96k | |
| Staff costs | €45 | €22k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €26k |
| Net profit | €-4k |
| Cash flow | €-2k |
| Staff costs | €45 |
| Income taxes | €597 |
| Dividends | - |
| Total assets | €119k |
| Equity | €61k |
| Debt | €58k |
| of which ≤ 1y | €58k |
| of which > 1y | - |
| Working capital | €57k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 1.97 |
| Quick ratio | 1.97 |
| Working capital ratio | 47.6% |
| Solvency | 50.9% |
| Debt / equity | 0.96 |
| Long-term debt ratio | - |
| Interest coverage | 0.97 |
| Gross margin | - |
| Net margin | - |
| ROA | -3.1% |
| ROE | -6.2% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €119k |
| Fixed assets | 21/28 | €4k |
| Tangible fixed assets | 22/27 | €4k |
| Current assets | 29/58 | €115k |
| Amounts receivable within one year | 40/41 | €358 |
| Cash & bank | 54/58 | €91k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €119k |
| Equity | 10/15 | €61k |
| Contributions / capital | 10/11 | €19k |
| Reserves | 13 | €76k |
| Accumulated profits (losses) | 14 | €-34k |
| Amounts payable | 17/49 | €58k |
| Amounts payable within one year | 42/48 | €58k |
| Trade debts payable within one year | 44 | €12k |
| Income statement | ||
| Gross operating margin | 9900 | €27k |
| Operating result | 9901 | €24k |
| Financial charges | 65 | €27k |
| Result before taxes | 9903 | €-3k |
| Income taxes | 67/77 | €597 |
| Net result for the period | 9904 | €-4k |
| Result to be appropriated | 9905 | €-4k |
| NACE primary | Human health(86940) |
| Legal form | Private limited company(610) |
| Incorporation | 01-03-2010 |
| Status | Active |
| Postal code | 7062 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 55028C0475/00L000 | Wallonia | 3,599 m² | 1 · 226 m² | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
23-02-2024 Transaction in capital or shares
Technical details
{
"events": [
{
"kind": "vzw_capital_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
}
],
"notary": {
"name": "Fran\u00E7ois No\u00E9",
"firm_city": null,
"firm_name": "Fran\u00E7ois NOE \u0026 Ga\u00EBtan LEMAIRE, Notaires associ\u00E9s",
"office_city": "Nivelles",
"is_associated": true
},
"act_meta": {
"language": "mixed",
"pub_date": "2024-02-23",
"filing_date": "2023-10-23",
"act_kind_objet": "Objet de l\u0027acte :"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2024-02-14",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": "2023-10-23"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0825.115.652",
"name_full": "INFIBE\u041C\u0410",
"legal_form": "SRL",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition du proc\u00E8s-verbal de l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire"
],
"shareholders_after": [],
"share_classes_after": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | INFIBEMA |